Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
RELATED: Can I start Wegovy at 2.4 mg
Appropriate monitoring will be necessary for GLP-1R agonists use in the treatment of patients with lipodystrophy
Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population
In this case, the target was a novel IGF-1, a protein important for bone and muscle health
